Wednesday, February 25, 2015
The global schizophrenia treatment market value is expected to undergo a modest increase over the coming decade, climbing from $6.3 billion in 2012 to $7.9 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 2.4%, according to a new report from research and consulting firm GlobalData.
Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, has found Roche/Chugai’s glycine transporter-1 inhibitor bitopertin is poised to be the first approved treatment to address negative symptoms in schizophrenia following its forecasted launch in the U.S. and Europe in 2016 and in Japan in 2017. As a first-in-class agent for the treatment of these prominent yet underserved symptoms of schizophrenia, Decision Resources expects bitopertin will garner nearly $1.5 billion in major-market sales in 2022.
Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of premium-priced agents will fuel 5% annual growth in the breast cancer market, with sales reaching more than $15 billion in 2022 in the U.S., France, Germany, Italy, Spain, the U.K. and Japan.